BACKGROUNDOption Agreement • October 15th, 1996 • Arqule Inc • Pharmaceutical preparations • New York
Exhibit 1.1 ----------- JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, $.01 par value, of ArQule, Inc. is filed on behalf of...Joint Filing Agreement • February 14th, 2003 • Arqule Inc • Pharmaceutical preparations
The undersigned hereby agree that the Statement on Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, $.01 par value, of ArQule, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
LEASELease Agreement • May 6th, 2005 • Arqule Inc • Pharmaceutical preparations • Massachusetts
ArQule, Inc. (a Delaware corporation) 9,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 25th, 2019 • Arqule Inc • Pharmaceutical preparations • New York
ArQule, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Leerink LLC (“SVB Leerink”) and RBC Capital Markets, LLC (“RBC Capital Markets”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Leerink and RBC Capital Markets are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $.01 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 1,387,500 additional shares of Common Stock. The aforesaid 9,250,000 shares of Common S
Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT dated as of December 8, 1998 (the "Execution Date") by and between ArQule, Inc., a Delaware corporation (the "Company") with its principal offices at 200 Boston Avenue, Medford, Massachusetts...Employment Agreement • May 11th, 1999 • Arqule Inc • Pharmaceutical preparations • Massachusetts
Exhibit 10.39 COLLABORATION AGREEMENT PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates ("Pfizer"), and ARQULE INC., a Delaware corporation, having an office at 19 Presidential...Common Stock Purchase Agreement • March 27th, 2002 • Arqule Inc • Pharmaceutical preparations • New York
SUBLEASEArqule Inc • December 21st, 1999 • Pharmaceutical preparations • Massachusetts
Exhibit 10.9 EMPLOYMENT AGREEMENT -------------------- EMPLOYMENT AGREEMENT dated as of July 9, 1996 by and between ArQule, Inc., a Delaware corporation (the "Company"), and James R. Fitzgerald, Jr. ("Executive"). WHEREAS, the Company desires to...Employment Agreement • October 15th, 1996 • Arqule Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.4 EMPLOYMENT AGREEMENT -------------------- EMPLOYMENT AGREEMENT dated as of July 21, 1999 (the "Execution Date") by and between ArQule, Inc., a Delaware corporation (the "Company") with its principal offices at 200 Boston Avenue, Medford,...Employment Agreement • November 15th, 1999 • Arqule Inc • Pharmaceutical preparations • Massachusetts
1 STOCK PLEDGE AGREEMENT AGREEMENT, made as of the 2nd day of November, 1995, between by and between Joseph C. Hogan, Jr. (the "Pledgor") and ArQule, Inc., a Delaware corporation with a principal place of business at 200 Boston Avenue, Medford,...Stock Pledge Agreement • October 15th, 1996 • Arqule Inc • Pharmaceutical preparations • Massachusetts
R E C I T A L SConsulting Agreement • August 9th, 2002 • Arqule Inc • Pharmaceutical preparations • Massachusetts
ARQULE, INC.Underwriting Agreement • April 3rd, 1997 • Arqule Inc • Pharmaceutical preparations • California
EXHIBIT 10.45 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") dated as of January 1, 2004 (the "Execution Date") is made by and between ArQule, Inc., a Delaware corporation (the "Company") with its principal offices at 19 Presidential...Employment Agreement • March 12th, 2004 • Arqule Inc • Pharmaceutical preparations • Massachusetts
BY AND AMONG ARQULE, INC.Agreement and Plan of Merger • February 1st, 2001 • Arqule Inc • Pharmaceutical preparations • Delaware
ArQule, Inc. Common Stock ($0.01 par value per share) Capital on Demand™ Sales AgreementArqule Inc • October 26th, 2016 • Pharmaceutical preparations • New York
Exhibit 99.2 LOAN MODIFICATION AGREEMENT This Loan Modification Agreement ("this Agreement") is made as of March 2, 2001 between ArQule, Inc., a Delaware corporation (the "Borrower") and Fleet National Bank (the "Bank"). The Bank is the successor by...Loan Modification Agreement • March 15th, 2001 • Arqule Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.1 AGREEMENT OF PURCHASE AND SALE THIS AGREEMENT OF PURCHASE AND SALE ("Agreement") is made as of April 28, 2005 ("Contract Date"), between (i) ARE- MA Region No. 20, LLC, a Delaware limited liability company ("Purchaser"), and (ii) ArQule,...Agreement of Purchase and Sale • May 6th, 2005 • Arqule Inc • Pharmaceutical preparations • Massachusetts
Exhibit 10.21 AMENDED AND RESTATED LEASE by and between ARE-MA Region No. 20, LLCLease • August 5th, 2005 • Arqule Inc • Pharmaceutical preparations • Massachusetts
1 September 23, 1996 BY FACSIMILE - 011 46 18 166301 & FED EX ---------------------------------------- Mr. Ulf Lundberg General Counsel Pharmacia Biotech AB Bjorkgatan 30 D-751 82 Uppsala, Sweden Re: Second Amendment to Option Agreement and Research...Option Agreement • November 14th, 1997 • Arqule Inc • Pharmaceutical preparations
INTRODUCTIONStrategic Alliance Agreement • May 7th, 2004 • Arqule Inc • Pharmaceutical preparations • Delaware
RECITALSDevelopment and License Agreement • March 17th, 1998 • Arqule Inc • Pharmaceutical preparations • Illinois
EXHIBIT 10.46 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") dated as of January 1, 2004 (the "Execution Date") is made by and between ArQule, Inc., a Delaware corporation (the "Company") with its principal offices at 19 Presidential...Employment Agreement • March 12th, 2004 • Arqule Inc • Pharmaceutical preparations • Massachusetts
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 10th, 2017 • Arqule Inc • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of January 6, 2017 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and ARQULE, INC., a Delaware corporation, with offices located at One Wall Street, Burlington, MA 01803 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
ARQULE, INC. 7,000,000 Shares Common Stock ($0.01 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2007 • Arqule Inc • Pharmaceutical preparations • New York
Each of the undersigned, Stephen A. Hill, President and Chief Executive Officer of ArQule, Inc., a Delaware corporation (the “Company”), and Richard H. Woodrich, Acting Chief Financial Officer of the Company, on behalf of the Company, does hereby certify pursuant to Section 6(j) of that certain Underwriting Agreement dated June 13, 2007 (the “Underwriting Agreement”) between the Company and, on behalf of the several Underwriters named therein, UBS Securities LLC, CIBC World Markets Corp, Leerink Swann & Co., Inc., Fortis Securities LLC and Rodman & Renshaw, LLC, that as of [date]:
1 2 1.3. "Analog Compound" means a chemical compound that [*****]. "ArQule Analog Compound" shall mean an Analog Compound developed from an ArQule Compound (as the parent compound) in the course of an optimization program by ArQule or SB as...Collaboration and License Agreement • May 1st, 2001 • Arqule Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.16 RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • March 12th, 2004 • Arqule Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.24.7 SECOND LOAN MODIFICATION AGREEMENT This Second Loan Modification Agreement ("this Agreement") is made as of September __, 2002 between ArQule, Inc., a Delaware corporation (the "Borrower") and Fleet National Bank (the "Bank"). The Bank...Second Loan Modification Agreement • November 13th, 2002 • Arqule Inc • Pharmaceutical preparations
1 Exhibit 10.1 AMENDMENT NO. 1 TO RESEARCH AND LICENSE AGREEMENT This Amendment No. 1, dated as of September 30, 1998 is between ArQule, Inc. ("ArQule") a Delaware Corporation and Roche Bioscience, a division of Syntex (U.S.A.) Inc. ("Roche...Research and License Agreement • November 16th, 1998 • Arqule Inc • Pharmaceutical preparations
EXHIBIT 10.40 TRIPLE NET SPACE LEASEWork Letter Agreement • May 15th, 2002 • Arqule Inc • Pharmaceutical preparations • California
EXHIBIT 10.1 RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 25th, 1998 • Arqule Inc • Pharmaceutical preparations • Delaware
ContractArqule Inc • February 22nd, 2018 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
RECITALSTermination of Agreement • March 12th, 2004 • Arqule Inc • Pharmaceutical preparations
January 26, 2001 Harold E. Selick 11 Somerset Court Belmont, CA 94002 RE: EMPLOYMENT TERMS Dear Mr. Selick: This letter agreement (the "Agreement") sets forth the terms and conditions of your employment with Camitro Corporation (the "Company") as the...Letter Agreement • March 22nd, 2001 • Arqule Inc • Pharmaceutical preparations • California
EXHIBIT 10.24.8 SECURITY AGREEMENT (ALL ASSETS EXCEPT INTELLECTUAL PROPERTY) SECURITY AGREEMENT (ALL ASSETS EXCEPT INTELLECTUAL PROPERTY) dated as of September ___, 2002 by and between ArQule, Inc., a Delaware corporation (the "Debtor") and Fleet...Security Agreement • November 13th, 2002 • Arqule Inc • Pharmaceutical preparations • Massachusetts
EMPLOYMENT AGREEMENTEmployment Agreement • March 1st, 2012 • Arqule Inc • Pharmaceutical preparations
This Employment Agreement (the “Agreement”) dated as of November 21, 2008 (the “Execution Date”) is made by and between ArQule, Inc., a Delaware corporation (the “Company”) with its principal offices at 19 Presidential Way, Woburn, Massachusetts 01801, and Thomas Chan (“Executive”) whose current principal residential address is 7 Stoney Brook Road, Hopkinton, MA 01748.
